Tempest Therapeutics Announces First Patient Dosed in TPST-1495 Clinical Study: Dual EP2/4 Antagonist Targeting Solid Tumors May 7, 2020
Owkin raises $25 million as it builds a secure network for healthcare analysis and research May 7, 2020
Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint in the Phase 3 ORIENT-12 Study as First-Line Therapy in Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer May 6, 2020
GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome May 4, 2020
Pharmaceutical Manufacturers and Wholesalers Continue to Choose TraceLink As Industry Readies for DSCSA Saleable Returns Verification Requirement April 29, 2020
Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio April 27, 2020